blogpost on pharma and biotech patents on the IPKat last week raised the question whether, given the fact that the pharma and biotech sector has so many legal issues that are largely unique to it, thought should be given to starting afresh with a sui generis for protecting innovation in the sector. This would obviously have major consequences not just for protection but also for litigation. A number of readers have already posted their comments on that blog, and readers of PatLit are invited to do so too.
Incidentally, the Forum's organisers are offering a 10% reduction on the registration fee for IPKat readers who quote the VIP Katcode 630IPKAT10. Further particulars and registration details are available here. There's also a pre-conference workshop here.